Published Date: 22 May 2023
Immune checkpoint inhibitors, or ICIs, are effective for HIV-positive people (PWH), according to a study published in the Journal of Clinical Oncology.
Read Full NewsTake 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 9, 2026.
A review of clinical trial and real-world data found no evidence that oral anticoagulants increase brain imaging abnormalities in patients treated with lecanemab or donanemab for early Alzheimer disease.
Angela Lek, PhD, chief research officer at the Muscular Dystrophy Association, provided an outlook on the 2026 MDA meeting and what clinicians should look forward to in preparation.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on epilepsy comorbidities!
Phase 3 Trial Supports Subcutaneous Anifrolumab in Systemic Lupus Erythematosus
5 Pulmonology Headlines You Missed in December 2025
Low Exercise Tolerance Before Kidney Transplant Signals Poor Muscle Recovery
1.
Could AI plus lasers help catch very early breast cancers?
2.
Mezigdomide Combinations Show Promise in Multiple Myeloma
3.
Colorectal Cancer Screening Uptake Tripled in 45-49 Age Group
4.
BTK Inhibitor Active in Half of Patients With Richter Transformation
5.
In Higher-Risk MDS, CMML, All-Oral Therapy Has Promise.
1.
Beyond the Blinders: A Review of Targeted Therapeutic Strategies for Triple-Negative Breast Cancer in 2025
2.
Cancer Trials 2025: Vaccines, Metabolic Targets, and the Microbiome in Oncology
3.
Revolutionizing Oncology: Pharmacometric Models in Personalized Cancer Drug Development
4.
Radiation Oncology Advances: Guidelines, Trials, Digital Tools & Education
5.
Screening Efficacy, Molecular Precision, and Therapeutic Revolutions in Lung Cancer 2025
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A New Era in Managing Cancer-Associated Thrombosis
2.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
3.
"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC
4.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part II
5.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation